Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.
2.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly.

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
3.

Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial.

Fleischhacker WW, Siu CO, Bodén R, Pappadopulos E, Karayal ON, Kahn RS; EUFEST study group.

Int J Neuropsychopharmacol. 2013 Jun;16(5):987-95. doi: 10.1017/S1461145712001241. Epub 2012 Dec 20.

PMID:
23253821
4.

[Metabolic side effects of risperidone in early onset schizophrenia].

Goeb JL, Marco S, Duhamel A, Kechid G, Bordet R, Thomas P, Delion P, Jardri R.

Encephale. 2010 Jun;36(3):242-52. doi: 10.1016/j.encep.2009.10.008. Epub 2009 Dec 1. French.

PMID:
20620267
5.

Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.

Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M.

Psychol Med. 2012 Jan;42(1):125-47. doi: 10.1017/S003329171100105X. Epub 2011 Aug 10. Review.

PMID:
21846426
7.

The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.

Falissard B, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, De Hert M.

Int Clin Psychopharmacol. 2011 Nov;26(6):291-302. doi: 10.1097/YIC.0b013e32834a5bf6.

PMID:
21876442
8.

Assessment of cardiovascular disease risk in patients with schizophrenia spectrum disorders in German psychiatric hospitals: results of the pharmacoepidemiologic CATS study.

Deuschle M, Paul F, Brosz M, Bergemann N, Franz M, Kammerer-Ciernioch J, Lautenschlager M, Lederbogen F, Roesch-Ely D, Weisbrod M, Kahl KG, Reichmann J, Gross J, Umbreit J.

Soc Psychiatry Psychiatr Epidemiol. 2013 Aug;48(8):1283-8. doi: 10.1007/s00127-013-0676-0. Epub 2013 Mar 21.

PMID:
23515714
9.

Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community.

Mackin P, Bishop D, Watkinson H, Gallagher P, Ferrier IN.

Br J Psychiatry. 2007 Jul;191:23-9.

10.

Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.

Poulin MJ, Chaput JP, Simard V, Vincent P, Bernier J, Gauthier Y, Lanctôt G, Saindon J, Vincent A, Gagnon S, Tremblay A.

Aust N Z J Psychiatry. 2007 Dec;41(12):980-9.

PMID:
17999270
11.

Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization.

Masand PS, Culpepper L, Henderson D, Lee S, Littrell K, Newcomer JW, Rasgon N.

CNS Spectr. 2005 Oct;10(10):suppl14 1-15.

PMID:
16404802
12.

Non-obese (body mass index < 25 kg/m2) Asian Indians with normal waist circumference have high cardiovascular risk.

Vikram NK, Pandey RM, Misra A, Sharma R, Devi JR, Khanna N.

Nutrition. 2003 Jun;19(6):503-9.

PMID:
12781849
13.

Overweight is an independent risk factor for cardiovascular disease in Chinese populations.

Zhou B, Wu Y, Yang J, Li Y, Zhang H, Zhao L.

Obes Rev. 2002 Aug;3(3):147-56.

PMID:
12164466
14.

Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.

Morrato EH, Druss B, Hartung DM, Valuck RJ, Allen R, Campagna E, Newcomer JW.

Arch Gen Psychiatry. 2010 Jan;67(1):17-24. doi: 10.1001/archgenpsychiatry.2009.179.

PMID:
20048219
15.

A four-year naturalistic prospective study of cardiometabolic disease in antipsychotic-treated patients.

Mackin P, Waton T, Watkinson HM, Gallagher P.

Eur Psychiatry. 2012 Jan;27(1):50-5. doi: 10.1016/j.eurpsy.2010.08.011. Epub 2010 Oct 30.

PMID:
21036552
17.

Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration.

Shi L, Ascher-Svanum H, Chiang YJ, Zhao Y, Fonseca V, Winstead D.

BMC Psychiatry. 2009 Dec 18;9:80. doi: 10.1186/1471-244X-9-80.

18.

Physical health of patients with severe mental illness: an intervention on medium secure forensic unit.

Vasudev K, Thakkar PB, Mitcheson N.

Int J Health Care Qual Assur. 2012;25(4):363-70.

PMID:
22755485
19.

A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.

Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD.

J Clin Psychiatry. 2008 Jul;69(7):1046-56.

PMID:
18605811
20.

Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.

McIntyre RS, Jerrell JM.

Arch Pediatr Adolesc Med. 2008 Oct;162(10):929-35. doi: 10.1001/archpedi.162.10.929.

PMID:
18838645
Items per page

Supplemental Content

Write to the Help Desk